Application of hypertonic saline in children with acute bronchitis

Introduction. Cough is the most common manifestation of respiratory infections of the upper and lower respiratory tract and indicates impaired mucociliary clearance. The cause of cough must be determined to choose the management tactics for children with cough. The most commonly used mucoactive drugs liquefy sputum as a result of a direct action of the components on the tracheobronchial secretion and/or mucosa of the respiratory tract. Given the mucoactive effect of hypertonic salines, we conducted an open clinical study of the effectiveness of 3% hypertonic saline with hyaluronic acid in acute bronchitis in children.

Aim of the study. To evaluate the clinical effect of 3% hypertonic saline with hyaluronic acid in acute bronchitis in children.

Materials and methods. Clinical efficacy and safety of 3% hypertonic saline with hyaluronic acid in 50 patients aged 3 to 12 years old with acute bronchitis were evaluated in the dynamics on the 1st, 3rd, 7th days of treatment with the score assessment of symptoms (cough, stuffy nose, auscultation data) and an indication of adverse events (if any).

Results. Improvement of condition was noted in most patients by the 3rd day of therapy (mean score 1.88 ± 0.3), temperature normalized in all patients, manifestations of rhinitis decreased. By the 5th day of treatment, the intensity of cough did not exceed 1 point in all patients (0.7 ± 0.14 points). According to the patient’s diary data, by the 7th day of treatment 74% of the children had no cough. On the 7th day of treatment, some children had a rare residual cough (0.36 ± 0.06 points), minor rhinitis (0.16 ± 0.1 points). No rales were heard in the lungs in all patients, rigid breathing was heard in 11 patients (mean score 0.22 ± 0.05).

Conclusions. The conducted study demonstrated that 3% hypertonic saline with hyaluronic acid is an effective drug in the treatment of cough in acute bronchitis in children.

1. Jurca M., Ramette A., Dogaru C.M., Goutaki M., Spycher B.D., Latzin P. et al. Prevalence of cough throughout childhood: A cohort study. PLoS ONE. 2017;12(5):e0177485. https://doi.org/10.1371/journal.pone.0177485.

2. Begic E., Begic Z., Dobraca A., Hasanbegovic E. Productive Cough in Children and Adolescents - View from Primary Health Care System. Med Arch. 2017;71(1):66-68. https://doi.org/10.5455/medarh.2017.71.66-68.

3. Weinberger M., Fischer A. Differential diagnosis of chronic cough in children. Allergy Asthma Proc. 2014;35(2):95-103. https://doi.org/10.2500/aap.2014.35.3711.

4. Geppe N.A., Kozlova L.V., Gorelov A.V., Kondyurina E.G., Malakhov A.B., Abdrakhmanova S.T. et al.. Acute respiratory tract infections in children. Diagnosis, treatment, prevention: a clinical guide. 2nd ed. Moscow: MedKom-Pro; 2020. 254 p. (In Russ.) Available at: https://ph.medcompro.ru/wp-content/uploads/2021/05/OIDP-verstka-05.11-1-15-1.pdf.

5. Worrall G. Acute cough in children. Can Fam Physician. 2011;57(3):315-318. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056681.

6. Denisova A.R., Dronov I.A. Mucolytic drug acetylcysteine in pediatric practice: myths and reality. Praktika pediatra = Pediatrician Practice. 2014;(6):20-25. (In Russ.) Available at: https://medi.ru/docplus/j01141220.htm.pdf.

7. O’Grady K.F., Grimwood K., Sloots T.P, Whiley D.M., Acworth J.P. et al. Upper airway viruses and bacteria and clinical outcomes in children with cough. Pediatr Pulmonol. 2017;52(3):373-381. https://doi.org/10.1002/ppul.23527.

8. Chang A.B., Oppenheimer JJ., Weinberger M.M., Rubin B.K., Grant C.C., Weir K., Irwin R.S. Management of Children With Chronic Wet Cough and Protracted Bacterial Bronchitis: CHEST Guideline and Expert Panel Report. Chest. 2017;151(4):884-890. https://doi.org/10.1016/j.chest.2017.01.025.

9. Baranov A.A., Namazova-Baranova L.S., Tatochenko V.K., Bakradze M.D., Polyakova A.S., Kulichenko T.V. et al. Acute bronchitis in children: clinical guidelines. 2018. (In Russ.) Available at: https://library.mededtech.ru/rest/documents/cr_239.

10. Geppe N.A., Malakhov A.B., Zaytseva O.V., Degtyareva M.V., Ilyenkova N.A., Kalyuzhin O.V. et al. Controversial and unresolved issues in the treatment of cough in children in outpatient practice. Pediatrics (Suppl. Consilium Medicum). 2017;(4):40-45. (In Russ.) Available at: https://cyberleninka.ru/article/n/spornye-i-nereshennye-voprosy-v-terapii-kashlya-u-detey-v-ambulatornoy-praktike.

11. Goralski J.L., Wu D., Thelin W.R., Boucher R., Button B. The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018;51:1702652. https://doi.org/10.1183/13993003.02652-2017.

12. Laube B.L., Sharpless G., Carson K.A., Kelly A., Mogayzel Jr. PJ. et al. Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulm Med. 2011;11:45. https://doi.org/10.1186/1471-2466-11-45.

13. Wills PJ., Hall R.L., Chan W., Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest. 1997;99(1):9-13. https://doi.org/10.1172/JCI119138.

14. King M., Dasgupta B., Tomkiewicz R.P, Brown N.E. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med. 1997;156(1):173-177. https://doi.org/10.1164/ajrccm.156.1.9512074.

15. Carro L.M., Martinez-Garcia M.A. Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review. Ther Adv Respir Dis. 2019;13:1-15. https://doi.org/10.1177/1753466619866102.